Orthocell Limited (OCC.AX)

AUD 1.25

(-0.4%)

Market Cap (In AUD)

299.62 Million

Revenue (In AUD)

5.31 Million

Net Income (In AUD)

-7.18 Million

Avg. Volume

172.01 Thousand

Currency
AUD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.35-1.27
PE
-
EPS
-
Beta Value
0.855
ISIN
AU000000OCC6
CUSIP
Q71504106
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Paul Frederick Anderson
Employee Count
-
Website
https://orthocell.com
Ipo Date
2014-08-12
Details
Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia. The company offers CelGro, a naturally derived collagen medical device for use in multiple indications to augment the surgical repair of bone, peripheral nerves, tendons, and cartilage; and Ortho-ATI, a cell therapy for treatment of chronic tendon injuries. It also provides Ortho-ACI, an autologous chondrocyte implantation to treat articular cartilage defects in the knee and ankle; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental application; and Remplir, a collagen scaffold used in peripheral nerve repair. Orthocell Limited was incorporated in 2006 and is headquartered in Murdoch, Australia.